Proactive Investors - Run By Investors For Investors

ReNeuron's Michael Hunt discusses very encouraging long-term stroke data

Michael Hunt, chief financial officer at ReNeuron Group Plc (LON:RENE) updates Proactive on their phase II clinical study treating stroke patients with its CTX stem cells.

Hunt says the positive response rates reported at three months after treatment were sustained at 12 months after treatment, with seven people still showing a “clinically relevant improvement”.

Meet Alliance Pharma PLC, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full RENE profile View Profile

ReNeuron Group PLC Timeline

December 19 2018

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use